Asia-Pacific NSCLC market to more than double to $6.2bn by 2023
pharmafile | March 21, 2017 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo
New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific (APAC) region is set to grow by more than 100% to be worth $6.2 billion by 2023, up from $3 billion in 2016. The advent of key therapies including BMS’ Yervoy (ipilimumab) and necitumumab, also known as Eli Lilly’s Portrazza is given as primary drivers of this growth.
Another key development in the region is the approval of immune-checkpoint inhibitors including BMS’ Opdivo, which has received marketing authorisation in Australia, South Korea and Japan, and MSD’s Keytruda, which so far has only been approved in Japan, but will soon move to widen that approval through data generated in current Phase 3 trials.
“Owing to strong clinical performances, immune-checkpoint inhibitors will have a greater uptake than other second-line market entrants and will compete among themselves for market share in the APAC region,” GBI Analyst Gayathri Kanika explained. “Chemotherapy will remain an integral aspect of NSCLC treatment, with platinum-based regimens being crucial in the first-line setting for all patients and docetaxel being a key therapy for second-line patients.”
Kanika also expects the market share of generic medications to shrink as a result of these targeted therapies entering the market. Interestingly, she also notes that this influx of new medicines will increase market segmentation and affect the determination of treatment options: “Broadly speaking, histological and molecular characterisation of tumours will play an even more important role in determining the best treatment options in the NSCLC market.”
Finally, these premium therapies will also have an effect on the impact of patent expiries within the sector, as Kanika notes: “The entry of targeted therapies into the market will offset the effect of patent expiries for drugs such as Avastin, Alimta, and Tarceva, which will have a limited impact on the market between 2016 and 2023. Indeed, the limited effect of patent expiry on the NSCLC market is one of the main reasons for the substantial growth in value expected in the forecast period, as the introduction of numerous premium therapies will not be offset by generic erosion.”
Matt Fellows
Related Content
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 …
Merck shares results for Keytruda in cervical cancer treatment
Merck, known as MSD outside of the US and Canada, has announced positive results from …
